Ochoa et al., 2017 - Google Patents
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cellsOchoa et al., 2017
View PDF- Document ID
- 6138637075499716700
- Author
- Ochoa M
- Minute L
- Rodriguez I
- Garasa S
- Perez‐Ruiz E
- Inogés S
- Melero I
- Berraondo P
- Publication year
- Publication venue
- Immunology and cell biology
External Links
Snippet
Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of cell‐to‐cell cytolysis executed by immune cells expressing FcRIIIA (CD16A). These effectors …
- 210000000822 Killer Cells, Natural 0 title abstract description 123
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ochoa et al. | Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells | |
| Vivier et al. | Natural killer cell therapies | |
| Li et al. | Tumor immunotherapy: new aspects of natural killer cells | |
| Hodgins et al. | Killers 2.0: NK cell therapies at the forefront of cancer control | |
| D’Aloia et al. | CAR-T cells: the long and winding road to solid tumors | |
| Patysheva et al. | Monocyte programming by cancer therapy | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Chester et al. | Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy | |
| US11648269B2 (en) | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof | |
| JP7573441B2 (en) | Guidance and navigation control proteins and methods for producing and using same - Patents.com | |
| Fan et al. | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia | |
| Wang et al. | NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy | |
| JP2021078514A (en) | COMPOSITIONS OF CHIMERIC ANTIBODY RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, AND METHODS OF USE THEREOF | |
| Baysal et al. | The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies | |
| CN107847587B (en) | Combination of a CD30 × CD16 antibody and a PD-1 antagonist | |
| Roberts et al. | Immunotherapy of childhood sarcomas | |
| Rajasekaran et al. | Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment | |
| US20180002427A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| KR20250022235A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| Chen et al. | Natural killer cells: the next wave in cancer immunotherapy | |
| AU2020373899A1 (en) | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product | |
| Kim et al. | Current trends and innovative approaches in cancer immunotherapy | |
| Gao et al. | The role of bone marrow microenvironment on CAR‐T efficacy in haematologic malignancies | |
| Baysal et al. | The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via | |
| Pachynski et al. | NK Cell Responses in Immunotherapy: Novel Targets and Applications |